Case | Cardiovascular complications | Age (years), sex | Malignancy | ICI | Days from first ICI administration to cardiovascular irAEs | Days from non-cardiovascular irAEs to cardiovascular irAEs | Management | Outcome |
---|---|---|---|---|---|---|---|---|
1 | Paf | 66, M | Renal cancer | Nivolumab | 64 | 15 | Pilsicainide | Survived |
2 | Paf | 71, M | NSCLC | Pembrolizumab | 35 | 25 | Anticoagulant therapy | Survived |
3 | AFL | 44, F | NSCLC | Nivolumab | 4 | (-) | Bisoprolol | Cancer death |
4 | PSVT | 72, F | NSCLC | Nivolumab | 89 | 65 | Bisoprolol | Cancer death |
5 | VT | 71, M | Melanoma | Pembrolizumab | 6 | (-) | Catheter ablation | Survived |
6 | AP | 74, M | NSCLC | Nivolumab | 201 | (-) | PCI | Survived |
7 | AP | 79, M | NSCLC | Nivolumab | 1102 | 986 | Nitrous acid | Survived |
8 | VSP | 58, M | Melanoma | Pembrolizumab | 294 | 204 | Nitrous acid | Survived |
9 | Pericardial effusion | 45, M | NSCLC | Pembrolizumab | 59 | 58 | Pericardial drainage | Cancer death |
10 | Pericardial effusion | 45, M | NSCLC | Pembrolizumab | 253 | 246 | Pericardial drainage | Cancer death |
11 | PE | 77, F | NSCLC | Pembrolizumab | 161 | (-) | Anticoagulant therapy | Survived |
12 | HF | 71, M | NSCLC | Nivolumab | 72 | (-) | Diuretics | Cancer death |
13 | Fulminant myocarditis | 59, M | Melanoma | Ipilimumab  →  Nivolumab | 495 | 418 | MCS + PSL pulse | Survived from myocarditis, Cancer death |
14 | Myocardial vasculitis | 79, F | Melanoma | Pembrolizumab | 263 | 74 | PSL | Survived |